<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428051</url>
  </required_header>
  <id_info>
    <org_study_id>0887X1-900</org_study_id>
    <secondary_id>B1841004</secondary_id>
    <nct_id>NCT00428051</nct_id>
  </id_info>
  <brief_title>Colombia Epidemiologic Surveillance Study</brief_title>
  <acronym>LEAP II</acronym>
  <official_title>Multinational Latin American Epidemiologic Surveillance For Invasive Pneumococcal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the reduction in invasive pneumococcal disease (IPD) after the
      introduction of a National Immunization Program with PCV-7 in Bogota. The original LEAP study
      determine incidence of IPD prior to introduction of PCV-7 in Brazil, Costa Rica and Colombia.
      LEAP II is the continuation of the study in Colombia only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was stopped based on a decision to include PCV 10 in the National Immunization
      Program in Colombia. The study was designed to measure the impact of PCV 7 and 13 and is no
      longer feasible.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annual age specific incidence rate of invasive pneumococcal disease based on the number of identified cases from the study sites and the size of the population at risk for children 28 days to 36 months of age</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">32867</enrollment>
  <condition>Pneumonia</condition>
  <condition>Meningitis</condition>
  <condition>Bacteremia</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>All eligible patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surveillance</intervention_name>
    <description>No study drug, only interventions are blood draws and Chest X-rays</description>
    <arm_group_label>All eligible patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebral Spinal Fluid Pleural Fluid S. pneumoniae isolates
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Epidemiologic study that will include children 28 days to 36 months of age that meet
        entrance criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 28 days to 36 months of age

          -  Presenting to a participating facility with a measured temperature of 39 degrees C or
             higher within 24 hours prior to screening, or with clinical suspicion of pneumonia,
             meningitis, bacteremia, sepsis, or other invasive pneumococcal disease

        Exclusion Criteria:

          -  Any patient hat based on the clinical impression of the treating physician should not
             participate in the study: examples such as those with suspected dengue or urinary
             tract infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>074065-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Uruca</city>
        <state>San Jose</state>
        <zip>607-1159</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0887X1-900&amp;StudyName=Colombia%20Epidemiologic%20Surveillance%20Study</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <last_update_submitted>October 26, 2011</last_update_submitted>
  <last_update_submitted_qc>October 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidemiology</keyword>
  <keyword>Surveillance</keyword>
  <keyword>Streptococcal Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

